DOCSLIB.ORG

A A–803467, 98 Absorption, Distribution, Metabolism, Elimination

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A A–803467, 98 Absorption, Distribution, Metabolism, Elimination Index A Anxiety disorders, 55 A–803467, 98 APD. See Action potential duration Absorption, distribution, metabolism, Arrhythmias, 45, 46 elimination and toxicity Aryl sulfonamido indanes, 126–128, 130 (ADMET), 193 ATP-sensitive potassium channels (KATP Absorption, distribution, metabolism, channels), 61 excretion, and toxicity Atrial effective refractory period (AERP), 122, (ADMET), 68 124–126, 128, 129, 132, 138 Acetylcholine binding protein (AChBP), Autoimmune diseases, 254 61, 62, 64 AZD7009, 101 Acetylcholine receptor (AChR), 57, 64 Azimilide, 139 Action potential duration (APD), 120, 122, 123, 128, 132 B Action potentials, 243, 256, 259 Basis set, 69–70 ADME/T, 299, 304 b-Barrel membrane proteins AERP. See Atrial effective refractory period genome-wide annotation, 13 Agitoxin (AgTX), 60 machine-learning techniques Agonists, 59–61, 64 residue pair preference, 11 Alinidine, 40–42 TMBs, 10 ALS. See Amyotrophic lateral sclerosis pipeline, genomic sequences, 14 Alzheimer, 55, 61 statistical method, 9–10 AMBER, 61, 65 Bending hinge, 64 2-Amino–2-imidazolidinone, 123, 125 Benzanilide, 256–257 Ammi visnaga, 254 Benzimidazolone, 256–257 b-Amyloid peptide (Ab), 62–63, 65 Benzocaine, 140 Amyotrophic lateral sclerosis (ALS), 90, 94, Benzodiazepines, 245 101 Benzopyrane, 127–128 Anionic channel blockers Benzopyrans, 61, 246–251, 261 mechanism of action of, 329–330 Benzothiadiazine 1,1-dioxide, 252–254 Antagonists, 59, 60 Benzothiadiazines, 253 Antiarrhythmic, 65–66, 68, 99, 101 Benzothiazepine, 70 Antiarrhythmic agents Benzothiazine derivatives, 251–252 class I, 245 Benzotriazole, 256–257 class II, 245 Bestrophins, 321, 322, 330, 331 class III, 245 Big potassium channels (BK channels), Antidepressant, 65–67 256, 257 Antiepileptic, 46 Bupivacaine, 56, 58, 59, 64, 69, 140 S.P. Gupta (ed.), Ion Channels and Their Inhibitors, 341 DOI 10.1007/978-3-642-19922-6, # Springer-Verlag Berlin Heidelberg 2011 342 Index C agents acting on other Cl–channels Ca2+-activated chloride channels, 316–317, disulfonic stilbene, 327 321, 327, 330, 331 flufenamic acid, 327 Ca2+/calmudulin-dependent protein kinase II, indanylooxyacetic acid, 327, 328 317 niflumic acid, 327 Calcium antagonist, 271, 273–275, 278 NPPB, 327 Calcium channel, 69, 70 TS-TM-calix(4)arene, 327 Calcium ion channel blockers, 267–282 agents acting with chloride channel in cAMP. See Cyclic adenosine monophosphate muscle cells cAMP-dependent kinase, 316 anthracene–9-carboxylate, 324 Cancer, 55 DIDS, 324 breast, 91, 103 ethacrynic acid, 324, 325 prostatic, 91 furosemide, 324, 325 Carbamazepine, 93–98, 102 SITS, 324 Cardiac arrhythmias, 68 stilbene disulfonate, 324, 325 Cardiovascular, 55 Chloride ion channels Cardiovascular diseases, 86, 89–90, 99–101 activation of, 311, 317, 323 Carvedilol, 59 blockers of, 311, 322–330 Catalyst software, 259 classification of, 311–321 Cerius2, 259 gating mechanisms of, 311, 330 cGMP-dependent kinase, 316 human diseases related to, 322 Channelopathies, 85–89 mutations in, 311, 322, 331 Channels, 79–103 Chloroquine, 66 closed, 81, 83, 93 Cholecystokinin-B receptor antagonists, 245 open, 81–84 Chromane, 246 Channels and pores, 25 Chromanols, 249–251 CHARMM, 61 ChTX. See Charybdotoxin Charybdotoxin (ChTX), 60 Cilobradine, 41–43 Chemoinformatics, 298–303 CLC chloride channels Chloride intracellular channels (CLICs) Cl–permeation of, 314–315 biophysical properties of, 320–321 dimeric structure of, 312, 314 CLIC5B, 319–320 dimorphic existence of, 312 dimorphic form of, 320 double-barreled structure of, 312 family of, 320 family of, 312, 315–316 functions of, 321 gating of, 314–315 integral membrane protein form of, 321 pore of, 314–315 soluble globular protein form of, specification of, 315–316 320, 321 topological features of, 312–314 structure of, 320 CLICs. See Chloride intracellular channels Chloride ion channel blockers Clonidine, 40–42 agents acting at neuronal chloride channels Cluster analysis, 61 bicuculline, 323 Cognitive deficits, 88, 91 cyanotriphenylborate, 324 Combinatorial protocol in multiple linear pentylenetetrazole, 324 regression (CP-MLR), 248, 253 picrotin, 323 Comparative molecular field analysis picrotoxinum, 323 (CoMFA), 66–68 agents acting on epithelial chloride Comprehensive Descriptors for Structural and channels Statistical Analysis (CODESSA), arachidonic acid, 325, 326 244, 257 diphenylamine carboxylate, 325, 326 Computational chemistry, 58, 70 glibenclamide, 325, 326 Conductance, 57, 62–63, 69 gluconate, 325, 326 Continuum, 70 organic anions, 325 Coordination numbers, 70–71 Index 343 CP-MLR. See Combinatorial protocol in Epithelial cells multiple linear regression cystic fibrosis airway, 317, 322, 330 Cromakalim, 246–249 normal, 317 Cyclic adenosine monophosphate (cAMP), Epithelial Na+ conductance (ENaC), 316 35, 37–40 Epithelium reticulum (ER), 321, 331 Cystic fibrosis transmembrane conductance ERP. See Effective refractory period regulator (CFTR) Extracellular ligand-activated channels, 243 mutations in, 316 nucleotide binding folds (NBFs) of, 316, 317 F regulatory R domain of, 317 F15845, 101 structure of, 316, 317 f-channel, 39, 40, 43, 45 FLAP, 61 Functional discrimination, membrane proteins D channels and pores, 25 3D-approaches, 244 characteristic features, amino acid residues, Deformation, 64 21–23 Depolarization, 82, 84, 88–90, 92, 93 databases, 18–21 Descriptors, 61, 66–68 ion channel proteins, 26 DHPs. See Dihydropyridines transporters based on classes and families, Diabetes, 61 23–25 Dihydropyrazolopyrimidine, 136 transporters from globular proteins, 21 Dihydropyridines (DHPs), 268–279, 281, 282 Dipole moments, 70 Diseases, 55, 57, 61 G 1,8-Disubstituted naphthalene, 130 GA. See Genetic algorithm 2,4-Disubstituted–1,2,3-triazoles, 124 GABA. See Gamma-aminobutyric acid 3D molecule representation of structures based GABA receptors on electron diffraction (3D MoRSE), blockers of, 323 253, 254 disorders associated with, 319 Docking, 58–64, 71 expression of, 319 1D-QSAR model, 206–207 functions of, 319 2D-QSAR model, 201–206, 244, 259 molecular structures of, 318–319 3D-QSAR model, 198–201 Gambierol toxin, 63 DRAGON, 244, 253 Gamma-aminobutyric acid (GABA), 58–60 “Drain plug” model, 196 Gating, 56, 57, 59–60, 64 Dronedarone, 122 Gating mechanism, 59, 60, 62 Drug-induced QT prolongation Genetic algorithm (GA), 58 cardiac repolarization, 161 Genetic function approximation (GFA), 244 class-III antiarrhythmic drugs, 161–162 Genetic partial least squares (G/PLS), 244 drug development, 160 Geometry optimizations, 69–70 proarrhythmic drugs, 162–163 Ginkgolide, 59 ventricular action structure, 161 Glycine receptor (GlyR), 59, 64 Drug trapping, 218–220 blockers of, 323 G/PLS. See Genetic partial least squares GRIND, 61 E Gromacs, 61 EasyDock, 60 Effective refractory period (ERP), 120 Electrostatic potential, 60 H Endoplasmic reticulum (ER), 156 Hanatoxin (HaTx1), 58–60 Ensemble, 67–68 hASIC. See The human acid-sensing ion Epilepsy, 55, 86–87, 91–94, 96, 103 channel 344 Index HCN1. See Hyperpolarization-activated cyclic amiodarone, 173 nucleotide-gated 1 astemizole, 173–174 HD. See Huntington disease bepridil and cisapride, 174 Hepatitis C, 62 chemical structure, year of approval/ hERG. See The human ether-a-go-go related withdrawal and medical indication, gene 165–171 hERG channel inhibition domperidone and E–4031, 174 bad ADMET profile, 193 fluconazol and fluoxetine, 174–175 ligand-based approaches grepafloxacin and ketoconazole, 175 classification models, 207–216 levacetylmethadol, 175 1D-QSAR, 206–207 macrolides (erythromycin), 175–176 2D-QSAR, 201–206 mesoridazine and mibefradil, 176 3D-QSAR, 198–201 nelfinavir, 176 matched molecular pairs, 216–217 pimozide, 176–177 pharmacophore models, 195–198 prenylamine, 177 LQT syndrome, 193–194 risperidone, 177–178 structure sertindole and terfenadine, 178 C terminus domain role, 195 terodiline, 178 regions, 194 Kv 11.1 mutations, 153 structure-based approaches preclinical guidelines, 179–180 amino acids involvement, 220–222 properties, 153 binding affinity model, 225–226 protein trafficking binding interactions, 225 chemical chaperones, 157–158 docking results, 229–232 ER, 156 docking studies, 227–228 glycosylation, 156 drug trapping, 218–220 pharmacological restoration, 158 Gly648 role, 223 4-phenylbutyrate, 157 homology models, 217–218 protein synthesis, 157 hydrogen bonds with Thr623, Ser624 temperature-dependent induction, 157 and Val625, 222–223 QTc, 159–160 orthogonal binding site, 229 strategies, QT prolongation, 182–183 para-substituents influence on phenyl structure ring, 224–225 N-terminal region, 155 subunits involvement, 223–224 S5–P–S6 sequences, 151–152 hERG potassium (K+) channels, 258–260 S1–S4 segments, 152 activators VSDs, 155 MTX, 173 Tdp, 158–159 NS1643, 173 as therapeutic target, 163–164 NS3623, 173 voltage-gated, 151 PD–118057, 172 Hidden Markov model (HMM), 6–7 RPR260243, 172 Homology modeling, 62–63 assay to predict QT prolongation The human acid-sensing ion channel electrophysiological studies, (hASIC), 59 mammalian cell lines, 182 Human diseases related to Cl–channels in silico methods, 180–181 alcoholism, 322 in vitro assay, 181–182 Bartter syndrome, 322 in vivo method, 182 Best’s disease, 322 cardiovascular safety, 178–179 cystic fibrosis, 322 classification, 151, 154 glioma in brain, 322 clinical guidelines, 180 hyperekplexia, 322 drug-induced QT prolongation, 160–163 insomnia, 322 functions and dysfunctions, 155–156 myotonia congenita Becker, 322 inhibitors myotonia congenita Thomsen, 322 Index 345 The human ether-a-go-go related gene Lambert-Eaton, 55 (hERG), 58, 59, 62, 63,
Load more

Recommended publications
  • Development of a Quantitative PCR Assay for the Detection And
    bioRxiv preprint doi: https://doi.org/10.1101/544247; this version posted February 8, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Development of a quantitative PCR assay for the detection and enumeration of a potentially ciguatoxin-producing dinoflagellate, Gambierdiscus lapillus (Gonyaulacales, Dinophyceae). Key words:Ciguatera fish poisoning, Gambierdiscus lapillus, Quantitative PCR assay, Great Barrier Reef Kretzschmar, A.L.1,2, Verma, A.1, Kohli, G.S.1,3, Murray, S.A.1 1Climate Change Cluster (C3), University of Technology Sydney, Ultimo, 2007 NSW, Australia 2ithree institute (i3), University of Technology Sydney, Ultimo, 2007 NSW, Australia, [email protected] 3Alfred Wegener-Institut Helmholtz-Zentrum fr Polar- und Meeresforschung, Am Handelshafen 12, 27570, Bremerhaven, Germany Abstract Ciguatera fish poisoning is an illness contracted through the ingestion of seafood containing ciguatoxins. It is prevalent in tropical regions worldwide, including in Australia. Ciguatoxins are produced by some species of Gambierdiscus. Therefore, screening of Gambierdiscus species identification through quantitative PCR (qPCR), along with the determination of species toxicity, can be useful in monitoring potential ciguatera risk in these regions. In Australia, the identity, distribution and abundance of ciguatoxin producing Gambierdiscus spp. is largely unknown. In this study we developed a rapid qPCR assay to quantify the presence and abundance of Gambierdiscus lapillus, a likely ciguatoxic species. We assessed the specificity and efficiency of the qPCR assay. The assay was tested on 25 environmental samples from the Heron Island reef in the southern Great Barrier Reef, a ciguatera endemic region, in triplicate to determine the presence and patchiness of these species across samples from Chnoospora sp., Padina sp.
    [Show full text]
  • Treatment Protocol Copyright © 2018 Kostoff Et Al
    Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al PREVENTION AND REVERSAL OF ALZHEIMER'S DISEASE: TREATMENT PROTOCOL by Ronald N. Kostoffa, Alan L. Porterb, Henry. A. Buchtelc (a) Research Affiliate, School of Public Policy, Georgia Institute of Technology, USA (b) Professor Emeritus, School of Public Policy, Georgia Institute of Technology, USA (c) Associate Professor, Department of Psychiatry, University of Michigan, USA KEYWORDS Alzheimer's Disease; Dementia; Text Mining; Literature-Based Discovery; Information Technology; Treatments Prevention and reversal of Alzheimer's disease: treatment protocol Copyright © 2018 Kostoff et al CITATION TO MONOGRAPH Kostoff RN, Porter AL, Buchtel HA. Prevention and reversal of Alzheimer's disease: treatment protocol. Georgia Institute of Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/59311 COPYRIGHT AND CREATIVE COMMONS LICENSE COPYRIGHT Copyright © 2018 by Ronald N. Kostoff, Alan L. Porter, Henry A. Buchtel Printed in the United States of America; First Printing, 2018 CREATIVE COMMONS LICENSE This work can be copied and redistributed in any medium or format provided that credit is given to the original author. For more details on the CC BY license, see: http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License<http://creativecommons.org/licenses/by/4.0/>. DISCLAIMERS The views in this monograph are solely those of the authors, and do not represent the views of the Georgia Institute of Technology or the University of Michigan. This monograph is not intended as a substitute for the medical advice of physicians. The reader should regularly consult a physician in matters relating to his/her health and particularly with respect to any symptoms that may require diagnosis or medical attention.
    [Show full text]
  • 1 Gambierol 1 2 3 4 Makoto Sasaki, Eva Cagide, and 5 M
    34570 FM i-xviii.qxd 2/9/07 9:16 AM Page i PHYCOTOXINS Chemistry and Biochemistry 34570 FM i-xviii.qxd 2/9/07 9:16 AM Page iii PHYCOTOXINS Chemistry and Biochemistry Luis M. Botana Editor 34570 FM i-xviii.qxd 2/9/07 9:16 AM Page iv 1 2 3 Dr. Luis M. Botana is professor of Pharmacology, University of Santiago de Compostela, Spain. His group is a 4 world leader in the development of new methods to monitor the presence of phycotoxins, having developed 5 methods to date for saxitoxins, yessotoxin, pectenotoxin, ciguatoxins, brevetoxins, okadaic acid and dinophy- 6 sistoxins. Dr. Botana is the editor of Seafood and Freshwater Toxins: Pharmacology, Physiology and Detection, 7 to date the only comprehensive reference book entirely devoted to marine toxins. 8 ©2007 Blackwell Publishing 9 All rights reserved 10 1 Blackwell Publishing Professional 2 2121 State Avenue, Ames, Iowa 50014, USA 3 4 Orders: 1-800-862-6657 5 Office: 1-515-292-0140 6 Fax: 1-515-292-3348 7 Web site: www.blackwellprofessional.com 8 Blackwell Publishing Ltd 9 9600 Garsington Road, Oxford OX4 2DQ, UK 20 Tel.: +44 (0)1865 776868 1 2 Blackwell Publishing Asia 3 550 Swanston Street, Carlton, Victoria 3053, Australia 4 Tel.: +61 (0)3 8359 1011 5 6 Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, 7 is granted by Blackwell Publishing, provided that the base fee is paid directly to the Copyright Clearance Cen- 8 ter, 222 Rosewood Drive, Danvers, MA 01923.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Marine Natural Products and Their Potential Application in the Future
    AJSTD Vol. 22 Issue 4 pp. 297-311 (2005) MARINE NATURAL PRODUCTS AND THEIR POTENTIAL APPLICATION IN THE FUTURE Chau Van Minh*, Phan Van Kiem, and Nguyen Hai Dang Institute of Natural Products Chemistry, Vietnamese Academy of Science and Technology 18 Hoang Quoc Viet Road, Cau Giay, Hanoi, Vietnam Received 04 November 2005 1. INTRODUCTION Oceans are the diverse resource, which cover more than 70% of the earth’s surface. No doubt, with 34 of 36 phyla of life represented, oceans are the greatest biodiversity in the world [1]. They are the extraordinary natural source of microorganism, algae, sponge, coelenterate, bryozoan, mollusk, and echinoderm… Especially, on coral reef, where shelter more than 1000 species per m2. Surprisingly, there is only a small number of researches in this field. Therefore increasing research on marine natural source may provide good results for exploiting and developing valuable natural products which benefit for human. Marine environment is a rich source of biological and chemical diversity. The diversity has been unique source of chemical compounds of potential for pharmaceuticals, cosmetics, dietary supplements, and agrochemicals. Ecological pressure, including competitions for food and space, the fouling of predator and surface, has led to the evolution of secondary metabolites with various biological activities. Many organisms are soft bodies and/or unmoved, hardly survive with the threat from around environment. Hence they have evolved the ability to synthesize toxic compounds or obtain them from microorganism to defense against predator or to paralyze their prey. The questions such as, why do fish not eat particular algae? Why do two sponges grow and expand until they reach but not grow over each other? may be explained by these reasons.
    [Show full text]
  • Ep 0681833 B1
    Europäisches Patentamt *EP000681833B1* (19) European Patent Office Office européen des brevets (11) EP 0 681 833 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 9/14, A61K 9/18 of the grant of the patent: 13.06.2001 Bulletin 2001/24 (21) Application number: 95106396.5 (22) Date of filing: 28.04.1995 (54) Nasally administrable compositions Nasal verabreichbare Mittel Compositions administrables par voie intranasale (84) Designated Contracting States: (74) Representative: Kraus, Walter, Dr. et al AT BE CH DE DK ES FR GB IT LI LU NL PT SE Patentanwälte Kraus, Weisert & Partner Thomas-Wimmer-Ring 15 (30) Priority: 11.05.1994 JP 12077894 80539 München (DE) 02.03.1995 JP 6664095 (56) References cited: (43) Date of publication of application: EP-A- 0 588 255 EP-A- 0 648 498 15.11.1995 Bulletin 1995/46 • DATABASE WPI Week 9344, Derwent (73) Proprietor: DOTT RESEARCH LABORATORY Publications Ltd., London, GB; AN 93-348353 Yokohama-shi, Kanagawa 224 (JP) ’Pharmaceutical compsn. for admin. via blood vessels - contains microcrystalline calcium (72) Inventor: Yanagawa, Akira, Med. Dr. phosphate powder as carrier for e.g. insulin’ & Yokohama-shi, Kanagawa, 224 (JP) JP-A-05 255 095 (ADVANCE K.K.) 5 October 1993 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Neuroprotective Effects of Cromakalim on Cerebral Ischemia-Reperfusion (Ir) Injury and Aluminium Induced Toxicity in Rat Brain
    Innovare International Journal of Pharmacy and Pharmaceutical Sciences Academic Sciences ISSN- 0975-1491 Vol 6, Issue 6, 2014 Original Article NEUROPROTECTIVE EFFECTS OF CROMAKALIM ON CEREBRAL ISCHEMIA-REPERFUSION (IR) INJURY AND ALUMINIUM INDUCED TOXICITY IN RAT BRAIN *1PITHADIA ANAND BHARAT KUMAR, 2SHITAL PANCHAL *1Department of Pharmacology, Parul Institute of Pharmacy, Vadodara,2 Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India. Email: [email protected] Received: 29 Apr 2014 Revised and Accepted: 28 May 2014 ABSTRACT Objective: Preclinical studies have demonstrated that potassium channel openers show a neuroprotective effect on cerebral ischemia-reperfusion (IR) injury in rats. However, their mechanism of action and effects in brain stroke related disorders such as Alzheimer’s disease (AD) remain poorly understood. Hence present study was done to investigate the prophylactic use of the adenosine triphosphate-sensitive (ATP) potassium channel opener cromakalim on neurological function in rats with cerebral IR injury and its related disorders AD. Methods: Male Wistar rats were randomly assigned to 6 groups (n = 36): Normal control, aluminium chloride(AlCl3) control, AlCl3 Sham operated, ischemia reperfusion (IR) control, AlCl3-IR control and AlCl3-IR with cromakalim treatment. Cromakalim10 mg/kg intra peritonially (i.p.) was administered daily for 42 days in middle cerebral artery occluded rats treated with AlCl3. At 24 hours post-surgery, neurological score, brain hemisphere weight difference, brain acetylcholinestarase level, lipid peroxidation, Na+/K+ ATPase pump activity and super oxide dismutase level were measured. Results: Following cerebral ischemia-reperfusion injury along with aluminium chloride, neurological score,brain hemisphere weight difference, brain acetylcholinestarase level, malondialdehyde levels were significantly high while Na+/K+ ATPase pump activity and super oxide dismutase(SOD) levels were significantly lower in diseased animals (P < 0.05).
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,329,697 B2 Garbaccio Et Al
    US008329697B2 (12) United States Patent (10) Patent No.: US 8,329,697 B2 Garbaccio et al. (45) Date of Patent: Dec. 11, 2012 (54) IMIDIZO 1.2-APYRAZINES USEFUL AS (56) References Cited AHCY HYDROLASE INHIBITORS U.S. PATENT DOCUMENTS (75) Inventors: Robert M. Garbaccio, Lansdale, PA 4,507,294 A 3, 1985 Bristol et al. (US); Antonella Converso, Elkins Park, 56.6 f 3.3: Ret , al PA (US); Mark E. Fraley, North Wales, 4. W w Wa (a. PA (US); Timothy J. Hartingh, Blue 2004/0204429 A1 10, 2004 Yuan Bell, PA (US) FOREIGN PATENT DOCUMENTS WO WO 2009/108546 * 9/2009 (73) Assignee: Merck Sharp & Dohme Corp., OTHER PUBLICATIONS Rahway, NJ (US) Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.* (*) Notice: Subject to any disclaimer, the term of this Hackam, et al. JAMA, 296(14), 2006, 1731-1732.* patent is extended or adjusted under 35 * cited b U.S.C. 154(b) by 163 days. c1ted by examiner Primary Examiner — Douglas MWillis (21) Appl. No.: 12/811,911 (74) Attorney, Agent, or Firm — Kenrick L. Vidale; John C. Todaro (22) PCT Filed: Feb. 18, 2009 (57) ABSTRACT (86). PCT No.: PCT/US2O09/034344 The present invention is directed to AHCY inhibitors of for mula (I) which are useful in the treatment of diseases charac S371 (c)(1), terized by high homocysteine levels, such as Alzheimer's (2), (4) Date: Jul. 7, 2010 disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of (87) PCT Pub. No.: WO2009/108546 the compounds and compositions in the treatment of diseases PCT Pub.
    [Show full text]
  • Effect of Niflumic Acid on Noradrenaline-Induced Contractions of the Rat Aorta D.N
    Brifish Journal of Pharmacology (1996) 118, 1065-1071 1996 Stockton Press All rights reserved 0007-1188/96 $12.00 0 Effect of niflumic acid on noradrenaline-induced contractions of the rat aorta D.N. Criddle, R. Soares de Moura, l*I.A. Greenwood & *W.A. Large Departmento de Farmacologia, Centro Biomedico - IB, Universidade do Estado do Rio de Janeiro, Brasil and *Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 ORE 1 The effects of niflumic acid, an inhibitor of calcium-activated chloride channels, were compared with the actions of the calcium channel antagonist nifedipine on noradrenaline-evoked contractions in isolated preparations of the rat aorta. 2 The cumulative concentration-effect curve to noradrenaline (NA) was depressed by both nifedipine and niflumic acid in a reversible and concentration-dependent manner. The degree of inhibition of the maximal contractile response to NA (1 gM) produced by 10 gM niflumic acid (38%) was similar to the effect of 1 gM nifedipine (39%). 3 Contractions to brief applications (30 s) of 1 pM NA were inhibited by 55% and 62% respectively by 10 gM niflumic acid and 1 gM nifedipine. 4 In the presence of 0.1 Mm nifedipine, niflumic acid (10 gM) produced no further inhibition of the NA- evoked contractions. Thus, the actions of niflumic acid and nifedipine were not additive. 5 In Ca-free conditions the transient contraction induced by 1 gM NA was not inhibited by niflumic acid (10 Mm) and therefore this agent does not reduce the amount of calcium released from the intracellular store or reduce the sensitivity of the contractile apparatus to calcium.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]